clinical trial · NCT07158840
AK112 in Non-squamous Non-small Cell Lung Cancer (NSCLC)Patients With Actionable Genomic Alterations (AGA) Who Have Failed to Previous Tyrosine Kinase Inhibitor (TKI) Treatment
Akeso·phase2·not yet recruiting·n = 60
Non-Small Cell Lung CancerAK112
brief summary
AK112 in non-squamous non-small cell lung cancer patients with actionable genomic alterations (AGA) who have failed to previous tyrosine kinase inhibitor (TKI) treatment
started
Sep 5, 2025
primary completion
Sep 1, 2028
completion
Jun 1, 2029
last updated
Sep 8, 2025
official title
A Single Arm, Multi-center, Phase II Study of AK112 in Non-squamous Non-small Cell Lung Cancer (NSCLC) Patients With Actionable Genomic Alterations (AGA) Who Have Failed to Previous Tyrosine Kinase Inhibitor (TKI) Treatment
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol